Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06189820
Status:
RECRUITING
Last Update Posted:
2024-01-05
First Post:
2023-11-22
Brief Title:
Role of the Fibroblast Activation Protein FAP as Biomarker of Fibrotic Lung Diseases
Sponsor:
Erasme University Hospital
Organization:
Erasme University Hospital
Study Overview
Official Title:
Role of the Fibroblast Activation Protein FAP as Biomarker of Fibrotic Lung Diseases
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FAPIPET
Brief Summary:
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PETCT
Detailed Description:
To evaluate the use of the fibroblast activation protein FAP as a biomarker of fibrotic lung disease idiopathic pulmonary fibrosis IPF and non-IPF ILDs The study will include both analysis of FAP expression in samples stored in the biobank of the department of Pneumology BAL blood induced sputum and EBC cohort A and lung FAPI uptake on PETCT scans performed at the department of Nuclear Medicine
before and after the initiation of an antifibrotic therapy IPF or PPF cohort B
before and after the initiation of corticosteroid therapy in case of an acute exacerbation of ILD cohort C
before and after the initiation of an immunosuppressive drug in the context of non-IPF pulmonary fibrosis cohort D
before lung transplantation surgery or biopsy to correlate with FAP expression determined by immunohistochemical analysis IHC cohort E
before and after the initiation of an antifibrotic therapy IPF or PPF cohort B
before and after the initiation of corticosteroid therapy in case of an acute exacerbation of ILD cohort C
before and after the initiation of an immunosuppressive drug in the context of non-IPF pulmonary fibrosis cohort D
before lung transplantation surgery or biopsy to correlate with FAP expression determined by immunohistochemical analysis IHC cohort E
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None